Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 17/20 | 0.46 |
| ▸ | CA1 | P00915 | 17/20 | 0.46 |
| ▸ | CA2 | P00918 | 17/20 | 0.46 |
| ▸ | CA4 | P22748 | 17/20 | 0.46 |
| ▸ | CA7 | P43166 | 17/20 | 0.46 |
| ▸ | CA9 | Q16790 | 17/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387906 | 1.00 | TRPV1 (0.52) | TRPV1TRPM8CA12CA1CA2 | |
| SCHEMBL387907 | 1.00 | TRPV1 (0.52) | TRPV1TRPM8CA12CA1CA2 | |
| SCHEMBL997974 | 0.85 | TRPV1 (0.50) | TRPV1TRPM8CA12CA1CA2 | |
| SCHEMBL15206576 | 0.85 | TRPV1 (0.50) | TRPV1TRPM8CA12CA1CA2 | |
| SCHEMBL15205294 | 0.85 | TRPV1 (0.50) | TRPV1TRPM8CA12CA1CA2 | |
| SCHEMBL15206064 | 0.84 | TRPV1 (0.49) | TRPV1TRPM8CA12CA1CA2 | |
| SCHEMBL15205421 | 0.84 | TRPV1 (0.49) | TRPV1TRPM8CA12CA1CA2 | |
| SCHEMBL392349 | 0.83 | TRPV1 (0.54) | TRPV1TRPM8CA12CA1CA2 | |
| SCHEMBL392348 | 0.83 | TRPV1 (0.54) | TRPV1TRPM8CA12CA1CA2 | |
| SCHEMBL389068 | 0.78 | SYK (0.53) | TRPV1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101764-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101764-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101764-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| EP-2029610-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146759-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146759-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | TRPV1 514/4885TRPM8 1513/4885CA12 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.